RELAPSED AND REFRACTORY MULTIPLE MYELOMA
Clinical trials for RELAPSED AND REFRACTORY MULTIPLE MYELOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED AND REFRACTORY MULTIPLE MYELOMA trials appear
Sign up with your email to follow new studies for RELAPSED AND REFRACTORY MULTIPLE MYELOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Gene therapy builds Cancer-Killing cells inside you – no lab needed
Disease control Recruiting nowThis early-stage trial tests a new gene therapy called KLN-1010 for people with multiple myeloma that has come back or stopped responding to treatment. Instead of removing cells and engineering them in a lab, this therapy works inside the body to create special immune cells that …
Matched conditions: RELAPSED AND REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Kelonia Therapeutics, Inc. • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New pill takes aim at Hard-to-Treat myeloma
Disease control Recruiting nowThis early-stage trial tests an experimental oral drug called KTX-1001 in people with multiple myeloma that has returned or not responded to prior treatments. The drug works by blocking a protein that helps myeloma cells grow. The study will enroll 165 adults and will also test K…
Matched conditions: RELAPSED AND REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: K36 Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New combo aims to tackle Hard-to-Treat myeloma
Disease control Recruiting nowThis study tests two drugs, mezigdomide and elranatamab, together in people with multiple myeloma that has come back or stopped responding to prior treatments. The goal is to find the safest dose and see if the combination can shrink tumors. About 62 adults will take part in this…
Matched conditions: RELAPSED AND REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1, PHASE2 • Sponsor: Celgene • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
New pill cocktail aims to beat Hard-to-Treat myeloma
Disease control Recruiting nowThis phase 2 trial is testing whether a combination of three drugs (selinexor, venetoclax, and dexamethasone) can shrink tumors in people with a specific genetic subtype of multiple myeloma called t(11;14) that has come back or stopped responding to treatment. About 33 participan…
Matched conditions: RELAPSED AND REFRACTORY MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: University of Miami • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC